Zomedica Reports First Quarter 2025 Financial Results

Zomedica Corp, a veterinary health company, announced its financial results for Q1 2025, reporting $6.5 million in revenue, a 4% increase from the previous year. The company achieved a 68% gross margin and noted $65 million in liquidity. The revenue growth was driven by a 13% increase in consumable sales, particularly in their TRUFORMA and PulseVet products.

The therapeutic device segment saw an 8% revenue increase, while the diagnostics segment declined by 25%. International sales grew by 32%, contributing to the overall revenue increase. The company faced a net loss of $63.8 million, largely due to a non-cash impairment charge of $55.8 million caused by a decline in market capitalization.

Zomedica remains optimistic about its future prospects, focusing on expanding its product portfolio and strengthening its market position. Operating expenses, excluding the impairment charge, decreased by 9% from the previous year.